Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Luyao Gong

Showing results (11-20 of 17) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 17 results.
British Journal of Pharmacology|September 23, 2023
Mechanisms of sunitinib resistance in renal cell carcinoma and associated opportunities for therapeuticsYunxia Wang, Xiaolin Liu, Luyao Gong, et al.
Frontiers in Pharmacology|June 20, 2024
IL-23 inhibitor enhances the effects of PTEN DNA-loaded lipid nanoparticles for metastatic CRPC therapyXinlu Chen, Luyao Gong, Yuanyuan Wang, et al.
Iscience|July 23, 2024
CXCL3/TGF-β-mediated crosstalk between CAFs and tumor cells augments RCC progression and sunitinib resistanceYunxia Wang, Weihong Ding, Wenjing Hao, et al.
Journal of Nanobiotechnology|April 2, 2024
MiR26a reverses enzalutamide resistance in a bone-tumor targeted system with an enhanced effect on bone metastatic CRPCYuanyuan Wang, Jiyuan Chen, Luyao Gong, et al.
Nature Communications|August 23, 2024
Engineered minimal type I CRISPR-Cas system for transcriptional activation and base editing in human cellsJing Guo, Luyao Gong, Haiying Yu, et al.
Theranostics|August 27, 2025
PTEN restoration and CXCR2 depletion synergistically enhance the effect of enzalutamide and inhibit bone metastatic CRPCJiyuan Chen, Luyao Gong, Simeng Cao, et al.
Science (New York, N.Y.)|April 30, 2021
Toxin-antitoxin RNA pairs safeguard CRISPR-Cas systemsMing Li, Luyao Gong, Feiyue Cheng, et al.
Pageof 2

Showing results (11-20 of 17) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 17 results.
British Journal of Pharmacology|September 23, 2023
Mechanisms of sunitinib resistance in renal cell carcinoma and associated opportunities for therapeuticsYunxia Wang, Xiaolin Liu, Luyao Gong, et al.
Frontiers in Pharmacology|June 20, 2024
IL-23 inhibitor enhances the effects of PTEN DNA-loaded lipid nanoparticles for metastatic CRPC therapyXinlu Chen, Luyao Gong, Yuanyuan Wang, et al.
Iscience|July 23, 2024
CXCL3/TGF-β-mediated crosstalk between CAFs and tumor cells augments RCC progression and sunitinib resistanceYunxia Wang, Weihong Ding, Wenjing Hao, et al.
Journal of Nanobiotechnology|April 2, 2024
MiR26a reverses enzalutamide resistance in a bone-tumor targeted system with an enhanced effect on bone metastatic CRPCYuanyuan Wang, Jiyuan Chen, Luyao Gong, et al.
Nature Communications|August 23, 2024
Engineered minimal type I CRISPR-Cas system for transcriptional activation and base editing in human cellsJing Guo, Luyao Gong, Haiying Yu, et al.
Theranostics|August 27, 2025
PTEN restoration and CXCR2 depletion synergistically enhance the effect of enzalutamide and inhibit bone metastatic CRPCJiyuan Chen, Luyao Gong, Simeng Cao, et al.
Science (New York, N.Y.)|April 30, 2021
Toxin-antitoxin RNA pairs safeguard CRISPR-Cas systemsMing Li, Luyao Gong, Feiyue Cheng, et al.
Pageof 2